Managing Refractory Cytomegalovirus Post-Solid Organ Transplant
Investigating HLH: Our Current Understanding of a Rare Disease
Managing Refractory Cytomegalovirus After Hematopoietic Cell Transplant
Understanding the Key Role of FcRn in Anti-AChR Antibody Positive gMG
Nicholas J. Silvestri, MD, FAAN
PeerExamining 2 Treatment Options for Anti-AChR Antibody Positive gMG: An Overview of the Trial Designs
Charulatha P. Nagar, MD
PeerTreating Anti-AChR Antibody Positive gMG: Clinical Trials for 2 Treatment Options
Tuan H. Vu, MD
PeerUnderstanding the Dosing and Administration of 2 Treatment Options for Anti-AChR Antibody Positive gMG
Jennifer Buczyner, MD
PeerUnderstanding Individualized Treatment Goals for gMG
Beth Stein, MD
PeerSupporting Adult Patients With Anti-AChR Antibody Positive gMG in Their Treatment Journeys: A Look at a Program
Andrew Gordon, MD
PeerAdvances in BPDCN Treatment: Targeting Its Pathophysiology
James Foran, MD
PeerManaging BPDCN as a Targeted Treatment Option
An Approach to Treating BPDCN Patients with Prior or Concomitant Hematologic Malignancies
Bennett H. Myers, MD
PeerBispecific Antibody Treatment in Relapsed or Refractory Multiple Myeloma
Hereditary Angioedema: A Perspective on Prophylactic Treatment
Dr. Timothy Craig
Peer